(Reuters) - Germany’s Stada plans to bring a copy of Eli Lilly’s Forteo osteoporosis treatment to market, its chief executive said, as the generic drugmaker moves further into the risky field of so-called biosimilars.
Hartmut Retzlaff told Reuters exclusively in an interview that its partner, biotech development firm Richter-Helm, would develop a copy of synthetic hormone Forteo, and that Stada had secured the license to market it in Europe.
“We are preparing for a market launch in 2019,” said the CEO, who has been at the helm for 21 years. He added the company was in talks over another biosimilar that could be introduced in 2017 but declined to name it because a deal had not been struck.
Help employers find you! Check out all the jobs and post your resume.
